Cheviot Value Management LLC Boosts Position in Pfizer Inc. $PFE

Cheviot Value Management LLC grew its holdings in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 12.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 555,832 shares of the biopharmaceutical company's stock after buying an additional 59,656 shares during the quarter. Pfizer accounts for 1.5% of Cheviot Value Management LLC's portfolio, making the stock its 20th largest position. Cheviot Value Management LLC's holdings in Pfizer were worth $14,374,000 as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. Horizon Financial Services LLC increased its holdings in Pfizer by 174.8% in the 4th quarter. Horizon Financial Services LLC now owns 1,014 shares of the biopharmaceutical company's stock valued at $25,000 after purchasing an additional 645 shares in the last quarter. YANKCOM Partnership acquired a new position in shares of Pfizer during the fourth quarter worth about $28,000. Grey Fox Wealth Advisors LLC acquired a new position in shares of Pfizer during the third quarter worth about $29,000. Darwin Wealth Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $32,000. Finally, Torren Management LLC purchased a new stake in shares of Pfizer in the fourth quarter worth about $34,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Pfizer Stock Performance

Shares of PFE opened at $25.65 on Friday. The business's 50 day moving average is $27.14 and its two-hundred day moving average is $26.16. Pfizer Inc. has a 52-week low of $21.97 and a 52-week high of $28.75. The firm has a market cap of $146.17 billion, a price-to-earnings ratio of 19.58 and a beta of 0.35. The company has a quick ratio of 0.87, a current ratio of 1.25 and a debt-to-equity ratio of 0.67.

Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The business had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. Pfizer had a net margin of 11.83% and a return on equity of 19.44%. The business's quarterly revenue was up 5.4% compared to the same quarter last year. During the same quarter last year, the company earned $0.92 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. Analysts forecast that Pfizer Inc. will post 2.98 EPS for the current fiscal year.

Pfizer Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 6.7%. The ex-dividend date of this dividend is Friday, May 8th. Pfizer's dividend payout ratio (DPR) is currently 131.30%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Scotiabank initiated a Buy view on Pfizer, adding to recent analyst confidence in the stock. Pfizer (PFE) Receives a Buy from Scotiabank
• Positive Sentiment: Erste Group slightly raised its FY2026 EPS estimate for Pfizer, reinforcing expectations that earnings remain stable and in line with consensus.
• Positive Sentiment: Recent coverage highlighted Pfizer’s Q1 beat, better-than-expected sales, and progress in its oncology pipeline, suggesting the company’s newer drugs are becoming more important to the investment story. How Pfizer’s Q1 Beat, Oncology Wins and Patent Deals At Pfizer (PFE) Has Changed Its Investment Story
• Positive Sentiment: Pfizer’s dividend remains a major draw for income investors, and a recent article argued that the high yield is still supported by management’s execution and cash flow. Pfizer's 6.5% Dividend Yield Looked Too Good to Be True -- but Management Just Silenced the Skeptics
• Neutral Sentiment: Pfizer is continuing to advance a new Phase 1 cancer trial, which signals ongoing investment in oncology but is still too early to materially change near-term financial results. Pfizer’s New Phase 1 Cancer Trial Signals Fresh Oncology Push for PFE Investors
• Neutral Sentiment: Pfizer was also mentioned in a cancer-care industry recognition announcement, but the item is mostly reputational and unlikely to move the stock on its own.
• Negative Sentiment: Pfizer halted an early-stage cancer study, and investors may view the termination as a small setback for its oncology pipeline, even if the financial impact is limited. Pfizer Terminates Early-Stage Cancer Trial: What It Means for PFE Investors
• Negative Sentiment: Pfizer ended another early-stage lymphoma combination trial, which adds to concerns that some pipeline programs may not advance as hoped. Pfizer Ends Early-Stage Lymphoma Combo Trial, Trimming a Small Piece of Its Oncology Upside

Wall Street Analysts Forecast Growth

PFE has been the topic of several analyst reports. HSBC raised their target price on Pfizer from $29.00 to $32.00 and gave the company a "buy" rating in a report on Tuesday, March 17th. UBS Group increased their price objective on shares of Pfizer from $25.00 to $27.00 and gave the company a "neutral" rating in a research report on Monday, April 13th. Citigroup lifted their price objective on shares of Pfizer from $26.00 to $27.00 and gave the company a "neutral" rating in a research note on Wednesday, April 29th. Bank of America reduced their target price on shares of Pfizer from $27.00 to $26.00 and set a "neutral" rating on the stock in a research report on Thursday, April 9th. Finally, Royal Bank Of Canada reaffirmed an "underperform" rating and set a $25.00 price target on shares of Pfizer in a report on Monday, April 20th. One equities research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the stock. Based on data from MarketBeat, Pfizer presently has a consensus rating of "Hold" and a consensus target price of $28.74.

About Pfizer

Pfizer Inc NYSE: PFE is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer's portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.